Vol.68 No.3 May 2020
Impact of rapid point-of-care molecular diagnostics for macrolide-resistant Mycoplasma pneumoniae at outpatient clinics
1)Sapporo Cough, Asthma, and Allergy Center, 1-32 South-4, West-15, Chuo-ku, Sapporo, Hokkaido, Japan
2)Idaimaeminamiyojo Internal Medicine Clinic
Abstract
Early diagnosis of Mycoplasma pneumoniae respiratory infection in outpatient clinics might be accomplished by changing the diagnostic test from serum antibody examination to rapid point-of-care molecular diagnostics using a throat swab. In Japan, a novel detection technique based on a quenching probe polymerase chain reaction has been developed. Two commercial devices for detecting macrolide-resistant M. pneumoniae are available; GENECUBE®M. pneumoniae and SmartGene® Myco. They can be used for automated gene analysis, including nucleic acid extraction, amplification, and detection of the macrolide-resistant strains A2063G and A2064G, within 30 to 50 minutes. These tests might be useful to ensure correct antimicrobial prescription by primary care doctors.
Key word
macrolide-resistant Mycoplasma pneumoniae, rapid detection, quenching probe, point of care molecular diagnostic
Received
December 20, 2019
Accepted
February 28, 2020
Jpn. J. Chemother. 68 (3): 371-375, 2020
